Development of a plectin-1 targeted payload delivery system for treating pancreat
开发用于治疗胰腺的 plectin-1 靶向有效负载递送系统
基本信息
- 批准号:8313566
- 负责人:
- 金额:$ 30.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-13 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:Adjuvant ChemotherapyAdverse effectsAdverse eventAffinityAnimalsBindingBiological MarkersCancer EtiologyCancer PatientCell LineCell surfaceCellsCessation of lifeClinicClinicalCombination Drug TherapyCytoplasmCytoplasmic ProteinDataDependovirusDevelopmentDiseaseDoseDrug Delivery SystemsDrug FormulationsDyesEpidermal Growth Factor ReceptorEsophagealExcisionFDA approvedGoalsHealthHumanImageIn VitroLeadLesionLiposomesLungMalignant NeoplasmsMalignant neoplasm of pancreasMetastatic LesionMetastatic Neoplasm to Lymph NodesMicrofilamentsModalityModelingMolecular GeneticsMusMuscleNeoplasm MetastasisOutcomeOutcome StudyOvarianPancreasPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPeptidesPeritoneumPermeabilityPhage DisplayPharmaceutical PreparationsPhasePremalignantPrimary NeoplasmProtein BindingPublicationsQualifyingQuality of lifeReagentRefractoryResearchSiteSkinSmall Business Innovation Research GrantSpecificityStagingSurfaceSurvival RateSystemTestingTherapeuticTherapeutic Clinical TrialTherapeutic InterventionToxic effectToxicologyTreatment EfficacyValidationWorkadvanced diseaseangiogenesisbasecancer cellcell growthcell killingchemotherapydesignflexibilitygemcitabineimprovedin vivoinnovationmouse modelnanoparticlenovelnovel therapeuticspancreatic cancer cellspancreatic neoplasmparticleplectinpre-clinicalprogramsresearch studyresponsesingle photon emission computed tomographysmall moleculesubcutaneoussuccesstargeted deliverytumortumorigenesistumorigenic
项目摘要
DESCRIPTION (provided by applicant): While only the 31st most common cause of cancer, pancreatic cancer is the fourth most common cause of cancer-related death in the US. Patients typically present with advanced disease that is notoriously refractory to chemotherapy. Indeed, the 5 year survival rate is below 5%. Radical resection with adjuvant chemotherapy is potentially curative, but less than 15% of patients qualify for resection (local disease). Despite decades of research, meaningful advancements in the therapeutic intervention of PDAC have been largely absent. In other oncologic indications, there have been several recent clinical successes in targeted tumor delivery of therapeutic payloads, and the first clinical product will likely be approved in the US in 2011. Therefore, the overall goal of this proposal is to develop a molecularly targeted nanoparticle based platform capable of being loaded with and targeting efficacious chemotherapies directly to pancreatic tumors. Recently, in a screen of cell surface markers of pancreatic cancer, we have identified a highly specific and novel cell surface biomarker, Plectin-1. Plectin-1 is normally a cytoplasmic protein predominantly expressed in the muscle and skin. But it is aberrantly surface expressed in in early, precancerous lesions as well as in 100% of human pancreatic tumors and metastatic lesions tested to date (N>100). Plectin-1 is up-regulated in a number of additional cancers including lung, ovarian and esophageal. A novel high-affinity and specific plectin-1 targeting peptide (PTP) that internalizes upon binding has been identified and thoroughly characterized. The proposed work has the long-term objective to develop a flexible therapeutic payload delivery platform capable of targeting to cells
expressing the biomarker plectin-1, such as pancreatic tumors. Outcomes from these studies will provide feasibility data on the ability to target cell- killing agents to various pancreatic cncer cell lines in vitro and in vivo. A lead product will be identified for advancing this work to a phae II effort focusing on product optimization, preclinical enabling toxicology and IND filing.
PUBLIC HEALTH RELEVANCE: The overall goal of this proposal is to develop a new drug delivery system that targets to a novel cancer tag for use in treating pancreatic cancer and other cancers. We will do this by making small particles that are capable of holding drugs and are targeted to the cancer through the use of tags that identify the cancer. The developed targeted drug delivery system will ultimately be used for delivery of numerous cell-killing agents specifically to cancer cells, potentially extending and improving cancer patient's lives.
描述(由申请人提供):在美国,胰腺癌仅是第31位最常见的癌症原因,但却是第4位最常见的癌症相关死亡原因。患者通常表现为晚期疾病,对化疗是出了名的难。事实上,5年生存率低于5%。根治性切除与辅助化疗是潜在的治愈,但不到15%的患者符合切除(局部疾病)的条件。尽管经过数十年的研究,PDAC的治疗干预在很大程度上没有取得有意义的进展。在其他肿瘤适应症中,最近在靶向肿瘤递送治疗有效载荷方面取得了一些临床成功,第一个临床产品可能于2011年在美国获得批准。因此,本提案的总体目标是开发一种基于分子靶向纳米颗粒的平台,能够装载并靶向直接针对胰腺肿瘤的有效化疗药物。最近,在胰腺癌细胞表面标志物的筛选中,我们发现了一种高度特异性的新型细胞表面生物标志物,Plectin-1。凝集素-1通常是一种主要表达于肌肉和皮肤的细胞质蛋白。但它在早期癌前病变以及100%的人类胰腺肿瘤和转移性病变中都有异常的表面表达(N bbb100)。Plectin-1在包括肺癌、卵巢癌和食道癌在内的许多其他癌症中上调。一种新的高亲和力和特异性的凝集素-1靶向肽(PTP)已被鉴定并彻底表征。这项工作的长期目标是开发一种能够靶向细胞的灵活的治疗有效载荷递送平台
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Greg Brian Fralish其他文献
Greg Brian Fralish的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Greg Brian Fralish', 18)}}的其他基金
Developing a plectin-1 targeted imaging agent for the detection of pancreatic can
开发用于检测胰腺癌的 plectin-1 靶向成像剂
- 批准号:
8200534 - 财政年份:2011
- 资助金额:
$ 30.13万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 30.13万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 30.13万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 30.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 30.13万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 30.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 30.13万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 30.13万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 30.13万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 30.13万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 30.13万 - 项目类别:
Discovery Grants Program - Individual